Also trades as: KYNB (NASDAQ) · $vol 0M
0IL8.L LSE
Kyntra Bio, Inc.
1W: -6.9%
1M: -24.0%
3M: -17.1%
YTD: -20.6%
1Y: -32.4%
3Y: -89.7%
$6.36
-0.51 (-7.42%)
Weekly Expected Move ±5.9%
$6
$6
$6
$7
$7
Overview
News
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$6M
-78.3% ▼
5Y CAGR: -48.4%
Gross Profit
$0
-100.0% ▼
Operating Income
-$46M
+69.5% ▲
Net Income
$183M
+485.6% ▲
EPS (Diluted)
$45.37
+9552.1% ▲
EBITDA
-$46M
+67.8% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $235M | $141M | $47M | $30M | $6M |
| YoY Growth | +33.5% | -40.2% | -66.7% | -36.7% | -78.3% |
| Cost of Revenue | $449M | $20M | $4M | $16M | $0 |
| Gross Profit | -$214M | $120M | $43M | $14M | $0 |
| Gross Margin | -90.9% | 85.6% | 91.5% | 47.5% | 0.0% |
| R&D Expenses | $387M | $297M | $266M | $96M | $24M |
| SG&A Expenses | $0 | $125M | $86M | $49M | $28M |
| Operating Expenses | $75M | $421M | $366M | $164M | $51M |
| Operating Income | -$289M | -$301M | -$323M | -$150M | -$46M |
| Operating Margin | -122.6% | -213.9% | -689.5% | -507.8% | -712.7% |
| Interest Expense | $1M | $1M | $8M | $8M | -$9M |
| Income Before Tax | -$290M | -$293M | -$323M | -$153M | -$58M |
| Tax Expense | $347K | $358K | -$252K | -$269K | -$90K |
| Net Income | -$290M | -$294M | -$284M | -$48M | $183M |
| Net Margin | -123.3% | -208.7% | -607.3% | -160.6% | 2848.6% |
| EPS (Diluted) | $-3.15 | $-3.15 | $-2.92 | $-0.48 | $45.37 |
| EBITDA | -$334M | -$283M | -$305M | -$142M | -$46M |
| Shares Outstanding | 92M | 94M | 97M | 100M | 4M |